Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology

Th17 Lymphocytes Induce Neuronal Cell Death in a Human iPSC-Based Model of Parkinson’s Disease

(2018) Annika Sommer et al.   Cell Stem Cell

Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson’s disease

(2018) Diego Grassi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A common antigenic motif recognized by naturally occurring human VH5–51/VL4–1 anti-tau antibodies with distinct functionalities

(2018) Adrian Apetri et al.   Acta Neuropathologica Communications

Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422 containing epitope on pathological tau

(2018) Jeroen van Ameijde et al.   Acta Neuropathologica Communications

T cells from patients with Parkinson’s disease recognize α-synuclein peptides

(2017) David Sulzer et al.   NATURE

α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies

(2017) Yvette C Wong et al.   NATURE MEDICINE

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy

(2017) Brian Spencer et al.   Acta Neuropathologica Communications

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers

(2016) Dale B. Schenk et al.   MOVEMENT DISORDERS

Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?

(2016) Abid Oueslati   Journal of Parkinsons Disease

Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson’s disease

(2015) Cassandra A. DeMarshall et al.   IMMUNOLOGY LETTERS

Active immunization therapies for Parkinson's disease and multiple system atrophy

(2015) Achim Schneeberger et al.   MOVEMENT DISORDERS

Inhibition of amyloid-β plaque formation by α-synuclein

(2015) Teresa Bachhuber et al.   NATURE MEDICINE

Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

(2014) D. Games et al.   JOURNAL OF NEUROSCIENCE

Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease: Sources of (Error) Variance in Biomarker Assays

(2014) Sebastian Heinzel et al.   PLoS One

α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration

(2014) Hien T. Tran et al.   Cell Reports

Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls

(2014) Beatriz Alvarez-Castelao et al.   Frontiers in Aging Neuroscience

Association of Parkinson Disease with Structural and Regulatory Variants in the HLA Region

(2013) William T. Wissemann et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons

(2013) Jing L. Guo et al.   CELL

Altered Serum IgG Levels to α-Synuclein in Dementia with Lewy Bodies and Alzheimer’s Disease

(2013) Niklas K. U. Koehler et al.   PLoS One

A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease

(2013) Penelope G. Foulds et al.   Scientific Reports

Antibody-Aided Clearance of Extracellular  -Synuclein Prevents Cell-to-Cell Aggregate Transmission

(2012) E.-J. Bae et al.   JOURNAL OF NEUROSCIENCE

Alpha-Synuclein Posttranslational Modification and Alternative Splicing as a Trigger for Neurodegeneration

(2012) Katrin Beyer et al.   MOLECULAR NEUROBIOLOGY

The many faces of α-synuclein: from structure and toxicity to therapeutic target

(2012) Hilal A. Lashuel et al.   NATURE REVIEWS NEUROSCIENCE

Correlation between Protective Immunity to a-Synuclein Aggregates, Oxidative Stress and Inflammation

(2012) Marina A. Gruden et al.   NEUROIMMUNOMODULATION

Naturally occurring  -synuclein autoantibody levels are lower in patients with Parkinson disease

(2012) D. Besong-Agbo et al.   NEUROLOGY

α-Synuclein and Anti-α-Synuclein Antibodies in Parkinson’s Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls

(2012) Lynnae M. Smith et al.   PLoS One

Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression

(2011) Marina A. Gruden et al.   JOURNAL OF NEUROIMMUNOLOGY

Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond

(2011) Tamar Shachar et al.   MOVEMENT DISORDERS

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

(2011) Eliezer Masliah et al.   PLoS One

Genome-Wide Association Study Confirms SNPs inSNCAand theMAPTRegion as Common Risk Factors for Parkinson Disease

(2010) Todd L. Edwards et al.   ANNALS OF HUMAN GENETICS

Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology

(2010) Ayse Ulusoy et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits  -Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions

(2010) K. E. Paleologou et al.   JOURNAL OF NEUROSCIENCE

Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease

(2010) Taye H Hamza et al.   NATURE GENETICS

Label-Free Detection of Biomolecular Interactions Using BioLayer Interferometry for Kinetic Characterization

(2009) Joy Concepcion et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

Invited Article: Nervous system pathology in sporadic Parkinson disease

(2008) H. Braak et al.   NEUROLOGY